Oligonucleotide (Antisense oligonucleotide) · Gene silencing: SCN1A · developed by Stoke Therapeutics
Zorevunersen (STK-001) is an antisense oligonucleotide administered by intrathecal injection. It is studied in Dravet syndrome, a severe epilepsy, and is designed to act on SCN1A RNA.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06872125 | Phase 3 | Dravet Syndrome | Active not recruiting | STOK |
| NCT04740476 | Phase 2 | Dravet Syndrome | Active not recruiting | STOK |
| NCT04442295 | Phase 1/2 | Dravet Syndrome | Completed | STOK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dravet Syndrome
Updated Nov 1, 2026. Something wrong or missing? Report it on the STOK page.
See STOK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STOK catalysts and pipeline →